Economic evaluation of work productivity gains associated with ribociclib (RIB) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) in the United States.

Authors: Adam Brufsky, Joseph A. Sparano, Sara M. Tolaney, Vk Gadi, Jason Shafrin, Xinglei Chai, Fan Yang, Zheng-Yi Zhou, Vaidyanathan Ganapathy, Corinth Auld, Gary Mark Sopher, Emma Alexander, Vamsi Bollu, Louis P. Garrison

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e23117

Source: Full article

---

Abstract

e23117